Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
Sangamo Therapeutics Inc (NASDAQ: SGMO) closed the day trading at $0.57 up 6.15% from the previous closing price of $0.54. In other words, the price has increased by $6.15 from its previous closing price. On the day, 5.65 million shares were traded. SGMO stock price reached its highest trading level at $0.589 during the session, while it also had its lowest trading level at $0.5368.
Ratios:
For a better understanding of SGMO, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.05 and its Current Ratio is at 1.05. In the meantime, Its Debt-to-Equity ratio is 1.20 whereas as Long-Term Debt/Eq ratio is at 1.20.
On December 10, 2024, H.C. Wainwright reiterated its Buy ratingand also kept the price unchanged to $10.
RBC Capital Mkts Downgraded its Outperform to Sector Perform on November 03, 2023, whereas the target price for the stock was revised from $6 to $2.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SGMO now has a Market Capitalization of 172939584 and an Enterprise Value of 158056880. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.12 while its Price-to-Book (P/B) ratio in mrq is 7.98. Its current Enterprise Value per Revenue stands at 1.934 whereas that against EBITDA is -2.712.
Stock Price History:
The Beta on a monthly basis for SGMO is 1.21, which has changed by -0.33720928 over the last 52 weeks, in comparison to a change of 0.13054323 over the same period for the S&P500. Over the past 52 weeks, SGMO has reached a high of $3.18, while it has fallen to a 52-week low of $0.41. The 50-Day Moving Average of the stock is 9.65%, while the 200-Day Moving Average is calculated to be -45.52%.
Shares Statistics:
Over the past 3-months, SGMO traded about 5.75M shares per day on average, while over the past 10 days, SGMO traded about 6742690 shares per day. A total of 301.71M shares are outstanding, with a floating share count of 292.13M. Insiders hold about 3.17% of the company’s shares, while institutions hold 17.09% stake in the company. Shares short for SGMO as of 1753920000 were 13656013 with a Short Ratio of 2.38, compared to 1751241600 on 24179412. Therefore, it implies a Short% of Shares Outstanding of 13656013 and a Short% of Float of 5.63.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
A comprehensive evaluation of Sangamo Therapeutics Inc (SGMO) is underway, with the input of 3 analysts contributing to its current rating.The consensus estimate for the next quarter is -$0.09, with high estimates of -$0.07 and low estimates of -$0.1.
Analysts are recommending an EPS of between -$0.37 and -$0.43 for the fiscal current year, implying an average EPS of -$0.41. EPS for the following year is -$0.3, with 3.0 analysts recommending between -$0.12 and -$0.4.
Revenue Estimates
5 analysts predict $34.4M in revenue for the current quarter. It ranges from a high estimate of $100M to a low estimate of $4M. As of the current estimate, Sangamo Therapeutics Inc’s year-ago sales were $49.41M
A total of 5 analysts have provided revenue estimates for SGMO’s current fiscal year. The highest revenue estimate was $124.7M, while the lowest revenue estimate was $34.7M, resulting in an average revenue estimate of $72.3M. In the same quarter a year ago, actual revenue was $57.8MBased on 5 analysts’ estimates, the company’s revenue will be $48.3M in the next fiscal year. The high estimate is $114.2M and the low estimate is $8.6M.
